SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives $11.00 Average PT from Analysts

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have been given a consensus recommendation of “Moderate Buy” by the ten brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $11.00.

Several brokerages have issued reports on SABS. HC Wainwright upped their price objective on SAB Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Jefferies Financial Group initiated coverage on SAB Biotherapeutics in a research report on Wednesday, May 20th. They set a “buy” rating and a $11.00 price target on the stock. Citigroup initiated coverage on SAB Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $11.00 price target on the stock. Zacks Research upgraded SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Rodman & Renshaw reiterated a “buy” rating and set a $13.00 price target on shares of SAB Biotherapeutics in a research report on Monday, May 11th.

Institutional Trading of SAB Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SABS. Dimensional Fund Advisors LP acquired a new stake in shares of SAB Biotherapeutics during the 3rd quarter worth approximately $32,000. ADAR1 Capital Management LLC acquired a new stake in SAB Biotherapeutics in the 3rd quarter valued at approximately $30,000. Virtu Financial LLC acquired a new stake in SAB Biotherapeutics in the 3rd quarter valued at approximately $40,000. Commodore Capital LP acquired a new stake in SAB Biotherapeutics in the 3rd quarter valued at approximately $8,847,000. Finally, RA Capital Management L.P. acquired a new stake in SAB Biotherapeutics in the 3rd quarter valued at approximately $8,847,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

SAB Biotherapeutics Trading Down 3.4%

Shares of NASDAQ SABS opened at $3.36 on Thursday. The stock’s 50 day moving average price is $3.76 and its two-hundred day moving average price is $3.87. SAB Biotherapeutics has a 52-week low of $1.60 and a 52-week high of $6.60. The stock has a market capitalization of $256.91 million, a P/E ratio of -1.59 and a beta of 0.54. The company has a quick ratio of 11.45, a current ratio of 11.45 and a debt-to-equity ratio of 0.01.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.15). On average, analysts anticipate that SAB Biotherapeutics will post -1.19 earnings per share for the current fiscal year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.